Cadrenal Therapeutics, Inc. Common Stock (CVKD) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.
The consensus price target is $32.00, representing an upside of 568.1% from the current price $4.79.
Analysts estimate Earnings Per Share (EPS) of $-7.60 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-8.73 vs est $-7.60 (missed -14.9%). 2025: actual $-6.64 vs est $-6.36 (missed -4.4%). Analyst accuracy: 91%.
CVKD Stock — 12-Month Price Forecast
$32.00
▲ +568.06% Upside
Average Price Target
Based on 1 Wall Street analysts offering 12-month price targets for Cadrenal Therapeutics, Inc. Common Stock, the price target is $32.00.
The average price target represents a +568.06% change from the last price of $4.79.
CVKD Analyst Ratings
Buy
Based on 1 analysts giving stock ratings to Cadrenal Therapeutics, Inc. Common Stock in the past 3 months
EPS Estimates — CVKD
91%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$8.73
vs Est –$7.60
▼ 12.9% off
2025
Actual –$6.64
vs Est –$6.36
▼ 4.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CVKD
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
